 | • レポートコード：MRC2301G121 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、254ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に7,985.76百万ドルであった世界の不眠症薬物治療市場規模が、2022年に8,488.55百万ドルに到達し、2027年まで年平均6.47%で成長して11,634.71百万ドルまで拡大すると予測しています。本レポートは、不眠症薬物治療の世界市場について調べ、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、治療薬別（一般医薬品、一般睡眠導入剤、一般睡眠サプリメント、処方薬）分析、治療別（市販型睡眠導入剤、処方型睡眠導入剤）分析、流通チャネル別（ドラッグストア、Eコマース、病院薬局、小売薬局、その他）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の構成でまとめております。また、Aa Pharma Inc、Actavis Totowa LLC、Altimed Pharma Inc.、Amneal Pharmaceuticals NY LLC、Direct_Rx、Ebb Therapeutics、Eisai Co., Ltd.、Foxland Pharmaceuticals, Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の不眠症薬物治療市場規模：治療薬別 - 一般医薬品における市場規模 - 一般睡眠導入剤における市場規模 - 一般睡眠サプリメントにおける市場規模 - 処方薬における市場規模 ・世界の不眠症薬物治療市場規模：治療別 - 市販型睡眠導入剤の市場規模 - 処方型睡眠導入剤の市場規模 ・世界の不眠症薬物治療市場規模：流通チャネル別 - ドラッグストアチャネルの市場規模 - Eコマースチャネルの市場規模 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - その他の市場規模 ・世界の不眠症薬物治療市場規模：地域別 - 南北アメリカの不眠症薬物治療市場規模 アメリカの不眠症薬物治療市場規模 カナダの不眠症薬物治療市場規模 ブラジルの不眠症薬物治療市場規模 … - アジア太平洋の不眠症薬物治療市場規模 日本の不眠症薬物治療市場規模 中国の不眠症薬物治療市場規模 インドの不眠症薬物治療市場規模 韓国の不眠症薬物治療市場規模 台湾の不眠症薬物治療市場規模 … - ヨーロッパ/中東/アフリカの不眠症薬物治療市場規模 イギリスの不眠症薬物治療市場規模 ドイツの不眠症薬物治療市場規模 フランスの不眠症薬物治療市場規模 ロシアの不眠症薬物治療市場規模 … - その他地域の不眠症薬物治療市場規模 ・競争状況 ・企業情報 |
The Global Insomnia Pharmacological Treatment Market size was estimated at USD 7,985.76 million in 2021 and expected to reach USD 8,488.55 million in 2022, and is projected to grow at a CAGR 6.47% to reach USD 11,634.71 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Insomnia Pharmacological Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Type, the market was studied across OTC Drugs, OTC Sleep Aids, OTC Sleep Supplements, and Prescription Drugs.
Based on Treatment, the market was studied across Over-the-Counter Sleep Aids and Prescription Sleep Aids. The Over-the-Counter Sleep Aids is further studied across Antihistamines, Melatonin, and Valerian Roots. The Prescription Sleep Aids is further studied across Benzodiazepines, Melatonin Receptor Antagonists, Non-benzodiazepines, and Orexin Antagonists. The Non-benzodiazepines is further studied across Eszopiclone, Zaleplon, and Zolpidem.
Based on Distribution Channel, the market was studied across Drug Stores, e-Commerce, Hospital Pharmacies, Others, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Insomnia Pharmacological Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Insomnia Pharmacological Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Insomnia Pharmacological Treatment Market, including Aa Pharma Inc, Actavis Totowa LLC, Altimed Pharma Inc., Amneal Pharmaceuticals NY LLC, Direct_Rx, Ebb Therapeutics, Eisai Co., Ltd., Foxland Pharmaceuticals, Inc., Fresenius Kabi USA, LLC, Hospira, Inc., Ingenus Pharmaceuticals, LLC, Meda Consumer Healthcare, Inc, MEDA Pharmaceuticals, MedPointe Pharmaceuticals, Merck & Co., Inc., Micro Labs Limited, Mylan N.V., Paratek Pharmaceuticals, Inc., Pernix Therapeutics, Pfizer Inc., Pro Doc Limitee, Purdue Pharmaceuticals L.P., Remedy Repack, Sanofi S.A., Sivem Pharmaceuticals Ulc, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceuticals Company Ltd., TriVue Pharmaceuticals, Inc., Vanda Pharmaceuticals, and Winthrop U.S..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Insomnia Pharmacological Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Insomnia Pharmacological Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Insomnia Pharmacological Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Insomnia Pharmacological Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Insomnia Pharmacological Treatment Market?
6. What is the market share of the leading vendors in the Global Insomnia Pharmacological Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Insomnia Pharmacological Treatment Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing stress level and physical disorders
5.1.1.2. Prevalence of chronic insomnia in adult patients
5.1.1.3. Rising awareness among patient and increasing visits to doctor regarding to insomnia
5.1.2. Restraints
5.1.2.1. Side effects associated with drugs
5.1.3. Opportunities
5.1.3.1. Development of novel products
5.1.3.2. Increase in penetration of new pharmaceuticals in developing areas
5.1.4. Challenges
5.1.4.1. Individual level stigma about insomnia in some patients
5.2. Cumulative Impact of COVID-19
6. Insomnia Pharmacological Treatment Market, by Drug Type
6.1. Introduction
6.2. OTC Drugs
6.3. OTC Sleep Aids
6.4. OTC Sleep Supplements
6.5. Prescription Drugs
7. Insomnia Pharmacological Treatment Market, by Treatment
7.1. Introduction
7.2. Over-the-Counter Sleep Aids
7.3.1. Antihistamines
7.3.2. Melatonin
7.3.3. Valerian Roots
7.3. Prescription Sleep Aids
7.4.1. Benzodiazepines
7.4.2. Melatonin Receptor Antagonists
7.4.3. Non-benzodiazepines
7.4.4.1. Eszopiclone
7.4.4.2. Zaleplon
7.4.4.3. Zolpidem
7.4.4. Orexin Antagonists
8. Insomnia Pharmacological Treatment Market, by Distribution Channel
8.1. Introduction
8.2. Drug Stores
8.3. e-Commerce
8.4. Hospital Pharmacies
8.5. Others
8.6. Retail Pharmacies
9. Americas Insomnia Pharmacological Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Insomnia Pharmacological Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Insomnia Pharmacological Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Aa Pharma Inc
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Actavis Totowa LLC
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Altimed Pharma Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Amneal Pharmaceuticals NY LLC
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Direct_Rx
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Ebb Therapeutics
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Eisai Co., Ltd.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Foxland Pharmaceuticals, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Fresenius Kabi USA, LLC
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Hospira, Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Ingenus Pharmaceuticals, LLC
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Meda Consumer Healthcare, Inc
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. MEDA Pharmaceuticals
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. MedPointe Pharmaceuticals
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Merck & Co., Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Micro Labs Limited
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Mylan N.V.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Paratek Pharmaceuticals, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Pernix Therapeutics
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Pfizer Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Pro Doc Limitee
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Purdue Pharmaceuticals L.P.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Remedy Repack
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Sanofi S.A.
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Sivem Pharmaceuticals Ulc
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Sumitomo Dainippon Pharma Co., Ltd.
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. Takeda Pharmaceuticals Company Ltd.
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services
13.28. TriVue Pharmaceuticals, Inc.
13.28.1. Business Overview
13.28.2. Key Executives
13.28.3. Product & Services
13.29. Vanda Pharmaceuticals
13.29.1. Business Overview
13.29.2. Key Executives
13.29.3. Product & Services
13.30. Winthrop U.S.
13.30.1. Business Overview
13.30.2. Key Executives
13.30.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing